Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis.
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in solid tumors remains inconclusive. Here, we report a systematic review and meta-analysis of the association between WT1 expression and prognosis in solid tumors. PubMed, Web of Science and Google Scholar were searched to identify studies exploring the impact of WT1 on clinical outcomes, including overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), relapse/recurrence-free survival (RFS) or progression-free survival (PFS), in solid cancer patients. Hazard ratio (HR) and 95% confidence interval (CI) were applied to assess the strength of these associations. Finally, a total of 29 eligible studies with 4090 patients were identified for qualitative analysis, and 22 studies with 3620 patients were enrolled for quantitative synthesis. Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21). Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35). In summary, our study suggests that WT1 may be a potential marker to predict DFS/RFS/PFS in solid tumor patients. Further studies are needed to confirm the role of WT1 expression in clinical practice.
1] Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China [2] Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.
Xiao-wei
XW
Qi
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Fan
F
Zhang
Department of Oncology, Luzhou Medical College, Luzhou, Sichuan, China.
Hong
H
Wu
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Jun-lan
JL
Liu
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Bei-ge
BG
Zong
1] Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China [2] Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Chuan
C
Xu
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Jun
J
Jiang
D014408:Biomarkers, Tumor / Q000378:metabolism*; D015897:Comorbidity; D018572:Disease-Free Survival; D006801:Humans; D015994:Incidence; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality*; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality*; D011379:Prognosis; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015996:Survival Rate; D025721:WT1 Proteins / Q000378:metabolism*
D014408:Biomarkers, Tumor; D025721:WT1 Proteins; C583751:WT1 protein, human